ALKS vs JNJ: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: JNJ is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ALKS and JNJ share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ALKS and JNJ exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Alkermes plc is an Ireland-domiciled, Nasdaq-listed biopharmaceutical company focused on the central nervous system. Its commercial base spans Vivitrol (extended-release naltrexone for alcohol and opioid dependence), Aristada (long-acting injectable for schizophrenia), and Lybalvi (an oral olanzapine/samidorphan combination for schizophrenia and bipolar I). In February 2026 it acquired Avadel Pharmaceuticals, adding Lumryz, a once-nightly sodium oxybate for narcolepsy, which broadened the portfolio into sleep medicine. The company is profitable on an adjusted basis and generates meaningful operating cash flow, which it uses to fund its pipeline rather than relying heavily on dilution.

Full ALKS guide

Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Its Innovative Medicine segment develops and sells branded prescription drugs across oncology, immunology, neuroscience, cardiovascular, and other areas, with major franchises that drive much of its profit. Its MedTech segment makes medical devices and surgical equipment for cardiovascular intervention, orthopedics, surgery, and vision care. J&J makes money by researching, manufacturing, and selling patented pharmaceuticals and devices to hospitals, physicians, pharmacies, and patients worldwide, supported by one of the largest research and development budgets in healthcare. The company is known for its diversification, financial strength, AAA-class balance sheet, and a multi-decade record of raising its dividend, making it a classic defensive blue chip. Founded in 1886 and headquartered in New Brunswick, New Jersey, J&J is a broadly held, large-cap healthcare company valued for stability, income, and a deep drug and device pipeline.

Full JNJ guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ALKS drivers: Orexin pipeline optionality; Cash-generative commercial base.
• JNJ drivers: Innovative Medicine pipeline; MedTech innovation and recovery.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Clinical outcomes are binary: a Phase 3 setback for alixorexton would remove the main growth thesis and could sharply reset the valuation. For JNJ, j&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ALKS if you believe its drivers more; JNJ if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ALKS and JNJ guides.

ALKS. First-quarter 2026 revenue of roughly $393 million rose about 28% year over year, helped by product growth and the newly consolidated Lumryz, though the quarter showed a GAAP net loss partly reflecting Avadel deal costs. Adjusted EBITDA of around $80 million underscores the underlying profitability of the marketed portfolio. At an approximately $8.5 billion market cap on roughly $1.5 billion of trailing revenue, the market is pricing in meaningful pipeline value beyond the current product base.

JNJ. J&J trades at a valuation typical of a large, defensive healthcare blue chip: a moderate multiple reflecting steady low-to-mid single-digit growth, high margins, and very strong cash generation, plus a discount for litigation and patent-cliff overhangs. The market values its diversification, balance-sheet strength, and long dividend record, pricing it as a stable income-and-quality holding rather than a growth stock.

Headline figures (approximate, July 2026): ALKS shows revenue (ttm) ~$1.5B, q1 2026 revenue ~$393M (+28% YoY), q1 2026 adj. ebitda ~$80M, q1 2026 gaap net loss ~$(67)M; JNJ shows revenue (ttm) ~$90 billion, operating margin ~25%, net income (ttm) ~$15 billion, p/e (ttm) ~16x.

ALKS and JNJ are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ALKS and JNJ exposure against your real portfolio. It is not an investment adviser.